Plaque Psoriasis

Guselkumab effectively cleared the skin of patients with moderate-to-severe plaque psoriasis across all skin tones, with significant improvements observed within the first 16 weeks of treatment.

Experts share practice pearls for managing patients with plaque psoriasis, highlighting the need to educate health care providers about any dermatologic therapy before they commit to treating a patient.

Experts discuss access to treatment as one of the biggest barriers in plaque psoriasis and highlight the importance of individualizing therapy for each patient.

Patients with moderate to severe scalp psoriasis treated with tildrakizumab exhibited sustained efficacy through week 52, demonstrating the long-term effectiveness and safety profile of this treatment.

Patients in the deucravacitinib group had higher response rates compared with placebo at week 16, regardless of the extent of baseline PASI score or BSA involvement.

Patients with scalp and body psoriasis who used nonsteroidal roflumilast foam .3% once daily experienced significant symptom improvement as early as 2 weeks.

Dr. Song spoke in this segment of his interview on several more insightful elements from his presentation titled ‘Early Dermatology Practice Pearls.’

Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.

Tildrakizumab significantly improved work productivity and reduced work activity impairment in patients with moderate to severe plaque psoriasis, highlighting this treatment's quality of life benefits.

Secukinumab treatment resulted in greater improvements compared with placebo at week 12, with responses increasing through week 52.

Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.

Linda Stein Gold, MD, explains how the safety considerations of nonsteroidal topicals must be weighed against their significant value in the treatment arsenal.

Linda Stein Gold, MD, discusses the notable transition in topical therapies for both psoriasis and atopic dermatitis, with the introduction of effective FDA-approved nonsteroidal treatments.

In this interview, Dr. Chovatiya touched on several important updates and recent developments in the JAK inhibitor space for dermatologists.

April Armstrong, MD, MPH, explains how early detection of psoriatic arthritis and psoriasis is critical to prevent irreversible joint damage and improve patient outcomes.

April Armstrong, MD, MPH, explains the effectiveness of interleukin (IL)-17 and IL-23 inhibitors in treating moderate to severe plaque psoriasis and psoriatic arthritis.

Mona Shahriari, MD, and Andrew F Alexis, MD, MPH, discussed the multifaceted considerations dermatologists should weigh when treating patients with skin of color diagnosed with plaque psoriasis.

Experts in dermatology comment on tapinarof and roflumilast, 2 nonsteroidal topical therapies recently approved for treatment of plaque psoriasis.

An expert shares considerations for choosing between an oral therapy and a biologic injection when treating plaque psoriasis.

Results of several clinical trials demonstrated the superior efficacy of risankizumab compared with apremilast or placebo.

Benjamin Lockshin, MD, explains the current landscape of oral medications for plaque psoriasis, emerging developments in treatment, and the importance of shared decision-making.

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

This new post-hoc analysis of ruxolitinib cream for those with eczema indicates that continued treatment past 8 weeks may lead to further benefit for those with the skin disease.

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, share approaches to implementing the newly approved TYK2 inhibitor, deucravacitinib, into the treatment algorithm of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, compares the efficacy, safety and dosing of 2 oral therapies, apremilast and deucravacitinib, for the treatment of plaque psoriasis.